[Efficacy of immunovenin in patients with community-acquired pneumonia].
To study efficacy of human immunoglobulin for intravenous administration (immunovenin) in the treatment of patients with community-acquired pneumonia (CAP). Two groups of CAP patients participated in the trial. Group 1 (n = 35) received standard therapy. Group 2 (n = 33) received standard therapy plus immunovenin. CAP patients had immune disorders. Combined treatment of CAP with administration of immunovenin relieved clinical symptoms of the disease, improved immunological status. Group 1 patients demonstrated symptoms of the disease and defects in immunity for a long time. Addition of immunovenin to standard therapy of CAP improves immunological parameters, efficacy of CAP treatment.